1. "2020"
Formats
  1. Journal Article (2337)
  2. Meeting Abstract (1901)
  3. Review (494)
  4. Editorial (342)
  5. Correspondence (121)
  6. Guidelines (114)
  7. Book Section (99)
  8. Research Letter (95)
  9. Miscellaneous (61)
  10. Conference Paper (33)
  11. Book Whole (2)
Groups
  1. Department of Medicine (2560)
  2. Solid Tumor Oncology Division (1535)
  3. GSK Faculty (1257)
  4. Sloan Kettering Institute Postdocs (1240)
  5. Hematologic Malignancies, Division of (936)
  6. Survivorship Research (930)

More Groups

People
  1. Jorge Reis-Filho (93)
  2. Miguel-Angel Perales (93)
  3. Sergio Giralt (91)
  4. Alexander Drilon (81)
  5. Britta Weigelt (76)
  6. Nadeem Abu-Rustum (71)

More People

Years
  1. 2020 (5599)
Publications
  1. Journal of Clinical Oncology (500)
  2. Blood (212)
  3. Cancer Research (185)
  4. Annals of Oncology (152)
  5. International Journal of Radiation Oncology, Biology, Physics (129)
  6. Laboratory Investigation (116)

More Publications

Publishers
  1. Elsevier Inc. (714)
  2. American Society of Clinical Oncology (548)
  3. Nature Publishing Group (385)
  4. American Association for Cancer Research (357)
  5. Oxford University Press (356)
  6. Springer (342)

More Publishers

Results (5599)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Meaning-centered psychotherapy for populations with unique psychosocial needs related to cancer and service-related trauma: Veterans and 9/11 first responders
    Meeting Abstract

    Roberts, K.
    Psycho-Oncology (2020)

    Fulltext@MSK | Save
  • Implementing meaning-centered psychotherapy for patients with advanced cancer and post-traumatic stress: Meeting the complex needs of coping with service-related cancer in veterans and 9/11 responders
    Meeting Abstract

    Roberts, K.
    Psycho-Oncology (2020)

    Fulltext@MSK | Save
  • Entrectinib in locally advanced / metastatic ROS1 and NTRK fusion-positive (NTRK plus ) non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    Meeting Abstract

    Springfeld, C.; de Braude, F.; Siena, S.; Barlesi, F.; Drilon, A.; Simmons, B.; Huang, X.; Pitcher, B.; Doebele, R. C.
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Entrectinib in patients with NTRK fusion-positive solid tumors or ROS1-positive NSCLC with CNS metastases
    Meeting Abstract

    Paz-Ares, L.; Dziadziuszko, R.; Drilon, A.; John, T.; Krebs, M.; Demetri, G.; Shaw, A. T.; Siena, S.; Wolf, J.; Farago, A. F.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Fight-202: A phase 2 study of pemigatinib in patients (PTS) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)
    Meeting Abstract

    Vogel, A.; Sahai, V.; Hollebecque, A.; Vaccaro, G.; Melisi, D.; Al-Rajabi, R.; Paulson, A. S.; Borad, M. J.; Gallinson, D.; Murphy, A. G.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Genomic landscape of entrectinib resistance from circulating tumor DNA (CTDNA) analysis in STARTRK-2
    Meeting Abstract

    Doebele, R. C.; Dziadziuszko, R.; Drilon, A.; Shaw, A. T.; Wolf, J.; Farago, A. F.; Dennis, L.; Riehl, T.; Simmons, B.; Wu, C.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Depth of response (DEPOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101
    Meeting Abstract

    Voss, M. H.; Motzer, R. J.; Albiges, L.; Rini, B.I.; Schmidinger, M.; Larkin, J.; Haanen, J. B. A. G.; Kollmannsberger, C.; Campbell, M. T.; Pal, S. K.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Safety and efficacy results from Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) In relapsed/refractory (R/R) large B-cell lymphoma (LBCL)
    Meeting Abstract

    Abramson, J.; Palomba, M. L.; Gordon, L.; Lunning, M.; Wang, M.; Arnason, J.; Mehta, A.; Purev, E.; Maloney, D.; Andreadis, C.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • POLO: Efficacy and health-related quality of life (HRQOL) with maintenance olaparib following first-line platinum-based chemotherapy (PBC) in patients (PTS) with a germline BRCA mutation and metastatic pancreatic cancer (MPC)
    Meeting Abstract

    Reinacher-Schick, A. C.; Kindler, H. L.; Hammel, P.; Reni, M.; Van Cutsem, E.; Mercade, T. M.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Oh, D. Y.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save
  • Checkmate 214 post hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma (ARCC) with sarcomatoid features (SRCC)
    Meeting Abstract

    Grimm, M. O.; McDermott, D. F.; Choueiri, T. K.; Motzer, R. J.; Frontera, O. A.; George, S.; Powles, T.; Donskov, F.; Harrison, M. R.; Rodriguez-Cid, J.; more...
    Oncology Research and Treatment (2020)

    Fulltext@MSK | Save